Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | CASP7 | P55210 | 2/20 | 0.66 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498703 | 0.94 | KDM4E (0.66) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL4320247 | 0.81 | KDM4E (0.57) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Alloxazine SCHEMBL499075 | 0.80 | KDM4E (1.00) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Alloxazine SCHEMBL29516835 | 0.80 | KDM4E (1.00) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Alloxazine SCHEMBL9619177 | 0.78 | KDM4E (0.96) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Lumichrome SCHEMBL29516827 | 0.77 | BLM (0.64) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Lumichrome SCHEMBL29861572 | 0.77 | BLM (0.64) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Lumichrome SCHEMBL194906 | 0.77 | BLM (0.64) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| Alloxazine SCHEMBL8745680 | 0.75 | BLM (0.81) | BLMTDP1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL31214551 | 0.73 | MAPT (0.62) | BLMTDP1KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211656-B2 | Biological targeting compositions and methods of using the same | THE INVENTION SCIENCE FUND I, LLC (US) | 2012-07-03 | — | — | US | claimed |
| US-20120134975-A1 | Biological targeting compositions and methods of using the same | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2012-05-31 | — | — | US | claimed |
| US-20100041133-A1 | Biological targeting compositions and methods of using the same | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-18 | — | — | US | claimed |
| US-20100041014-A1 | Biological targeting compositions and methods of using the same | ENTERPRISE SCIENCE FUND, LLC | 2010-02-18 | — | — | US | claimed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| EP-2294186-B1 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | INCURON INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| US-8486697-B2 | Inducing cell death by inhibiting adaptive heat shock response | INCURON, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2600904-A1 | ARTIFICIAL CELLS | Searete LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8211656-B2 | Biological targeting compositions and methods of using the same | THE INVENTION SCIENCE FUND I, LLC (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062384-A2 | REDUCED FLUENCE RATE PDT | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | BLM 979/4885TDP1 1970/4885KDM4E 3097/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | BLM 4110/4885TDP1 3101/4885KDM4E 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.